Take the Next Step

Enter your email address to stay informed with the latest information about portfolio monitoring

Magnifying Glass

Check for Losses!

Kaplan Fox has the experience, skills, and resources to aggressively pursue our clients' rights on issues of securities fraud.

Contact Us to Start

Current Case Investigations

Snap, Inc.

January 16, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Snap, Inc. (“Snap” or the “Company”) (NYSE: SNAP).  Investors who purchased Snap common stock between March 2, 2017 and August 10, 2017, inclusive (the “Class Period”) may be affected.

GreenSky, Inc.

January 15, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of GreenSky, Inc. (“GreenSky” or the “Company”) (NASDAQ: GSKY).  GreenSky is a financial technology company that runs an online platform for processing loan applications at the point of sale.

AxoGen, Inc.

January 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN), a company that purports to provide surgical solutions for physical damage or discontinuity to peripheral nerves.  AxoGen’s products include nerve allografts and extracellular matrices.  Investors who purchased AxoGen securities between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”) may be affected.

Alkermes plc

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or the “Company”) (NASDAQ: ALKS).  Investors who purchased Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Eastern District of New York against Alkermes, the Company’s Chairman and CEO, and its CFO on behalf of investors of Alkermes securities during the Class Period.

Immunomedics Inc.

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU).  Investors who purchased Immunomedics common stock between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of New Jersey against Immunomedics, the Company’s President and CEO, and its CFO on behalf of investors in Immunomedics common stock during the Class Period.

DXC Technology Company

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of DXC Technology Company (“DXC Technology” or the “Company”) (NYSE: DXC).  Investors who purchased DXC Technology common stock between February 8, 2018 and November 6, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Eastern District of Virginia against DXC Technology,  J. Michael Lawrie, the Company’s CEO, and Paul N. Saleh, the Company’s CFO, on behalf of investors in DXC Technology common stock during the Class Period.

Load More

Settlement Filing Deadlines

Company Ticker Class Period Deadline Administrator
Xencor, Inc. XNCR On behalf of all former holders of Xencor, Inc.'s (the "Company") Series A-E preferred stock whose shares were converted to A-1 stock in the Recapitalization. 5/13/17 Strategic Claims Services  
Molycorp, Inc. MCP 2/21/2012 - 10/15/2013 5/18/17 Angeion Group  
Health Enhancement Products, Inc. (N/K/A Zivo Bioscience, Inc.) HEPI 10/31/2003 - 5/31/2004 5/18/17 Rust Consulting, Inc.  
Barclays Bank PLC (Electronic Foreign Exchange Trading - BARX) n/a 6/1/2008 - 4/21/2016 5/19/17 Garden City Group  
EZCORP, Inc. EZPW 4/19/2012 - 10/6/2014 5/19/17 Garden City Group  
King Digital Entertainment plc KING 3/26/2014 - 9/22/2014 5/23/17 Gilardi & Co.  
Load More